Dr. Spencer Nadolsky and Karl sit down with Dr. Susan Brian to break down one of the most significant proposed changes in women's health in decades, the potential renaming and reclassification of polycystic ovarian syndrome to anovulatory androgen excess, and what that shift means for the millions of women who have been diagnosed, misdiagnosed, or dismissed under the current framework.

Dr. Spencer Nadolsky and Karl bring on Dr. Austin Baraki and Dr. Jordan Feigenbaum from Barbell Medicine to cut through the peptide hype and explain why most of the research peptides people are currently injecting have no randomized controlled trial data in humans, were abandoned by pharmaceutical companies because they failed or showed harm signals, and may not even contain what is on the label. The core message is simple: calling something a short chain amino acids does not make it safe, natural does not mean studied, and having a standard of evidence before putting something in your body is not being close minded it is basic medicine.

Dr. Spencer Nadolsky and Karl sit down with David W, a nurse practitioner who was actually enrolled in the Triumph 1 retatrutide phase 3 trial, to break down data just presented at the American Diabetes Association conference showing average weight loss of up to 30 percent and cardiometabolic benefits that go well beyond anything tirzepatide or semaglutide produce on their own. David went from 240 pounds to 167 in the trial and walks through exactly what the experience felt like from the inside while Spencer and Karl explain what the numbers mean for patients and clinicians waiting for this drug to reach the market.

2:26 PMClaude responded: Dr.Dr. Spencer Nadolsky and Karl break down two brand new randomized controlled trials, Surmount-Maintain and Attain-Maintain, that put hard numbers on what actually happens to patients when they try to lower their tirzepatide dose, switch to oral orforglipron, or come off GLP-1 medicines entirely after significant weight loss. The data confirms what they have been seeing clinically for years: obesity biology fights hard to pull weight back up, only about 17 percent of people can come off these medicines and maintain their results, and for most patients the conversation is not about stopping but about finding the most effective and affordable long-term dosing strategy.

Dr. Spencer Nadolsky and Karl sit down with Dr. Susan Brian, a Yale-trained endocrinologist and certified menopause provider who runs a bone fragility fracture clinic, to break down whether GLP-1 medicines are actually causing bone loss or whether the viral panic around this topic is getting ahead of the evidence. The short answer is that the medicines themselves do not appear to be the problem, the weight loss is, and there is a clear and well-established playbook for protecting your bones while on them.

Dr. Spencer Nadolsky and Karl sit down with Dr. Eryn Russo, a board-certified occupational and environmental medicine physician with nearly 20 years of experience treating real toxic metal exposures, to break down exactly why the heavy metal detox industry is built on tests that are not supported by any medical standard and treatments that can cause genuine harm. If an influencer has ever made you wonder whether lead, mercury, or cadmium is behind your symptoms, this is the episode that puts that fear to rest with actual science.

Dr. Spencer Nadolsky and Karl sit down with Dr. Adam Auton, geneticist at 23andMe, to break down a brand new paper using data from over 27,000 people that identified specific genetic variants in the GLP-1 receptor and GIP receptor that predict both how much weight someone loses on these medications and how likely they are to experience side effects. This is one of the first studies to show that precision medicine for GLP-1 drugs may already be closer than most people think.

Dr. Spencer Nadolsky and Karl sit down with Dr. Henning Langer, a PhD researcher at the Charité in Berlin, to break down his newly published paper combining rodent and human data to look directly at what GLP-1 medicines actually do to skeletal muscle beyond what a DEXA scan can tell you. From mice running to exhaustion on semaglutide to maximum voluntary contraction data in humans, this is the most granular conversation yet on whether these drugs are doing something to muscle that nobody fully understands yet.

Dr. Spencer Nadolsky and Karl sit down with Dr. Stuart Phillips, senior author on the newly updated American College of Sports Medicine position stand on resistance training, to break down what 137 systematic reviews and over 30,000 participants actually tell us about building muscle, getting stronger, and improving function across the lifespan. From rep ranges and training frequency to power development, eccentric loading, and why periodization may matter less than you think, this is the evidence-based conversation that cuts through 17 years of social media noise in one episode.

Dr. Spencer Nadolsky, Karl, and chief science officer Dr. Grant Tinsley sit down with Dr. Steven Heymsfield, physician at the Pennington Biomedical Research Center and lead author on the BELIEVE trial, to break down what happens when you combine bimagrumab with semaglutide and why over 90 percent of weight lost in the combination group was pure fat.